Clinical Trial Search

Primary: Change From Baseline in Mean "Off" Time — -0.9; -0.9; -0.8; -0.8 Hours/day — p=0.8700

Primary: Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living [ADL]) Score From Baseline to Month 3 — -2.5; -0.5 Units on a scale

Primary: Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to Week 4 — -3.7; -1.8 Units on a scale

Primary: Number of Participants With Any TEAE — 7; 18; 8; 32 Participants

Primary: Efficacy of 3 BIA 9-1067 (5 mg, 25 mg, and 50 mg) Compared With 200 mg of Entacapone or Placebo, — -56.0; -96.3; -91.3; -85.9 minutes

Primary: Change From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser…

Primary: Change From Baseline (BL) in Total Awake Time Spent "Off" at Week 4 of Maintenance Period — -1.91; -2.04; -2.92; -2.34 Hours — p=0.814

Primary: Change From Baseline in Mean "Off" Time (Hours Per Day) at Week 12 — -1.2; -1.0; -0.9; -0.5 Hours/Day — p=0.0564

Primary: Unified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 12 Months After Hospital Discharge — -2.1; 1.4 units…

Primary: Change From Baseline to Endpoint of 12 Weeks in the 3-day Average of Awake Time Per Day Spent in the "Off" State — -0.4; -1.3; -1.6; -1.7 hours/day — p=0.753

Primary: The Primary Objective of This Study is to Explore the Efficacy and Tolerability of DM-1992 Compared to a Standard CD/LD IR Formulation as Measured by Percent "OFF" Time…

Primary: Pulmonary Safety of CVT-301 Change From Baseline for FEV1. — 2.957; 3.117; -0.059; -0.078 Liters

Primary: Clinical Global Impression Scale — 21; 27 units on a scale

Primary: Change in Average Daily Hours of ON-time Without Troublesome Dyskinesia With Mesdopetam Compared to Placebo as Assessed With 24-hour Patient Home Diaries From Baseline…

Primary: Change From Pre-dose to 90 Mins. Post-dose in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Score After 4 Weeks of Dosing in Each…

Primary: Change From Baseline in Mean Daily OFF-time During Treatment Period — -0.51; -1.11; -1.35 hours per day — p=0.0006

Primary: Unified Parkinson Disease Rating Scale (UPDRS). — 12; 12; 10; 10 units on a scale

Primary: L-DOPA Insensitivity — 5 Participants — p=0.00468

Primary: Tapping Speed Task - Experiment 1 — 110.52; 128.89; 138.43; 145.86 taps/min

Primary: Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score — -1.2; -10.3 score on a…

Primary: Change in Systolic Blood Pressure From Supine to Tilt at 3 Minutes — -24.22; -20.32 mmHg

Primary: Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary — -1.24; -1.59 hours — p=0.3257

Primary: Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia — 0.97; 2.72 hours — p=0.0083

Primary: Unified Parkinson's Disease Rating Scale (UPDRS) Part III — -9.83; -5.91 units on a scale

Primary: Change From Baseline in Average "Off" Time (Hours Per Day) at Week 12 — -1.0; -1.1; -0.8 hours per day — p=0.4933

Primary: Percentage of Participants With Reduction in Adverse Events — 94; 86; 73; 84 percentage of participants

Primary: Assessment of the Effectiveness of Two Months of Use of the Remedee Endorphin Band Medical Device in Improving Motor Disorders in Patients With Parkinson's Disease — 6…

Primary: Change From Baseline in Domain 3 (Fluctuation-related Pain) of KING's PARKINSON's DISEASE PAIN SCALE (KPPS) — 17.2; 16.7; 17.1; 16.9 score on a scale

Primary: Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method…

Primary: Time To Intervention — 52.00; 42.00; NA; NA Days — p=0.803